Perceptive Advisors OBIO Position
Active3-Fund ConvergencePerceptive Advisors trimmed their position in Orchestra BioMed Holdings, Inc. (OBIO) in Q4 2025, holding $21.3M worth of shares across 5,127,256 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
OBIO is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Orchestra BioMed Holdings, Inc.
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Full company profile →Short Interest
2.0%
3.7 days to cover
Perceptive Advisors OBIO Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Decreased | 5,127,256 | -165,300 | $21.3M |
| Q3 2025 | Increased | 5,292,556 | +700,000 | $13.1M |
| Q2 2025 | Held | 4,592,556 | — | $12.3M |
| Q1 2025 | Held | 4,592,556 | — | $19.7M |
| Q4 2024 | Held | 4,592,556 | — | $18.4M |
| Q3 2024 | Increased | 4,592,556 | +2,046,675 | $23.6M |
| Q2 2024 | Held | 2,545,881 | — | $20.7M |
| Q1 2024 | Increased | 2,545,881 | +113,792 | $13.4M |
| Q4 2023 | Held | 2,432,089 | — | $22.2M |
| Q3 2023 | Increased | 2,432,089 | +379,221 | $21.2M |
| Q2 2023 | Decreased | 2,052,868 | -225,358 | $14.4M |
| Q1 2023 | New | 2,278,226 | +2,278,226 | $44.6M |
Frequently Asked Questions
Does Perceptive Advisors own OBIO?
Yes. As of Q4 2025, Perceptive Advisors holds 5,127,256 shares of Orchestra BioMed Holdings, Inc. (OBIO) valued at $21.3M. This data comes from their SEC 13F filing.
How many hedge funds own OBIO?
3 specialist biotech hedge funds currently hold OBIO, including RTW Investments, Boxer Capital. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Perceptive Advisors first buy OBIO?
Perceptive Advisors's position in OBIO was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Perceptive Advisors's OBIO position increasing or decreasing?
Perceptive Advisors trimmed their OBIO position in the most recent quarter, reducing by 165,300 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
OBIOCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Perceptive AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →